The pharmacology of resveratrol in animals and humans
The pharmacology of resveratrol in animals and humans
复制标题
DOI：
10.1016/j.bbadis.2015.01.014
复制
发表时间：
2015-06-01
影响因子：
6.2
通讯作者：
Pezzuto, John M.
中科院分区：
文献类型：
--
作者：
Park, Eun-Jung;Pezzuto, John M.
除了数千篇与白藜芦醇(RSV)有关的研究论文外，还发表了约300篇综述文章。早期的研究往往集中在RSV与心血管系统、炎症和癌症发生/发展相关的药理活性上。最近，通过探索RSV在衰老过程、糖尿病、神经功能障碍等方面的潜在影响，拓宽了我们的视野。在这里，我们主要关注过去5年(2009-2014)报道的RSV的体内药理效应。此外，对白藜芦醇最近进行的临床干预研究进行了总结。动物体内研究与临床研究之间或临床研究之间存在一些差异，这可能是由于RSV的不同剂量、实验环境和受试者的差异。尽管如此，许多哺乳动物的阳性指征已被报道，因此有理由主张进行更明确的临床研究。由于安全性描述是原始的，一个额外的优势是使用RSV作为膳食补充剂。这篇文章是题为：白藜芦醇：将临床前研究结果转化为改善患者结果的挑战的特刊的一部分。(C)2015爱思唯尔B.V.保留所有权利。
In addition to thousands of research papers related to resveratrol (RSV), approximately 300 review articles have been published. Earlier research tended to focus on pharmacological activities of RSV related to cardiovascular systems, inflammation, and carcinogenesis/cancer development. More recently, the horizon has been broadened by exploring the potential effect of RSV on the aging process, diabetes, neurological dysfunction, etc. Herein, we primarily focus on the in vivo pharmacological effects of RSV reported over the past 5 years (2009-2014). In addition, recent clinical intervention studies performed with resveratrol are summarized. Some discrepancies exist between in vivo studies with animals and clinical studies, or between clinical studies, which are likely due to disparate doses of RSV, experimental settings, and subject variation. Nevertheless, many positive indications have been reported with mammals, so it is reasonable to advocate for the conduct of more definitive clinical studies. Since the safety profile is pristine, an added advantage is the use of RSV as a dietary supplement This article is part of a Special Issue entitled: Resveratrol: Challenges in translating pre-clinical findings to improved patient outcomes. (C) 2015 Elsevier B.V. All rights reserved.